At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 314 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
In Brief
A Phase 2 clinical trial evaluating Baricitinib and Placebo for Systemic Lupus Erythematosus. Completed, enrolled 314 participants across 84 sites in 12 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesArgentina, Austria, France, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMar 2016
Primary CompletionOct 2017
Study CompletionNov 2017
TodayJul 2026
First PostedMar 15, 2016
Enrollment StartMar 24, 2016
Primary CompletionOct 12, 2017
Study CompletionNov 9, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.3 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally